title: Effects of modified collagen matrices on human umbilical vein endothelial cells.
abstract: The most commonly used biomaterials fail to ensure sufficient angiogenesis for fast in vivo incorporation. This results in central necrosis and consequent infection. One way of obtaining a high angiogenic response is the application of vascular endothelial growth factor (VEGF). To obtain a sustained release of these cytokines, heparin was incorporated into collagen matrices using 1-ethyl-3(3-dimethyl-aminopropyl) carbodiimide (EDC) and N-hydroxysuccinmide (NHS). The functionality of the heparinized collagen matrices was then enhanced by immobilization of VEGF via its heparin-binding domain. This procedure changed in vitro degradation behavior and water-binding capacity. Accelerated endothelial cell proliferation was also achieved. A range of different heparin and EDC/NHS concentrations in combination with VEGF induced variation in endothelial cell growth and tubulogenic formation. Polymerized collagen scaffolds presented biointeractive systems with integrated angiogenic activity. This may become a useful tool in the clinical therapy of disorders connected with wound healing.
authors.affiliation: Department of Plastic Surgery, Hand Surgery, Burn Unit, RWTH Aachen University, Aachen, Germany. mmarkowicz@ukaachen.de
authors.forename: M
authors.initials: M
authors.lastname: Markowicz
authors.forename: A
authors.initials: A
authors.lastname: Heitland
authors.forename: G C M
authors.initials: GC
authors.lastname: Steffens
authors.forename: N
authors.initials: N
authors.lastname: Pallua
mesh_terms: D049109:Cell Proliferation; D002478:Cells, Cultured; D024042:Collagen Type I / Q000737:chemistry*; D004338:Drug Combinations; D004730:Endothelium, Vascular / Q000187:drug effects*; D005022:Ethyldimethylaminopropyl Carbodiimide / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008854:Microscopy, Electron; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D013388:Succinimides / Q000494:pharmacology; D023822:Tissue Engineering / Q000379:methods*; D014471:Umbilical Veins / Q000166:cytology*; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology
chemical_list: D024042:Collagen Type I; D004338:Drug Combinations; D013388:Succinimides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D006493:Heparin; C001426:N-hydroxysuccinimide; D005022:Ethyldimethylaminopropyl Carbodiimide